ATE209036T1 - Verwendung von imidazo(a,5-a)quinolonen als neuroprotektive arzneimittel - Google Patents

Verwendung von imidazo(a,5-a)quinolonen als neuroprotektive arzneimittel

Info

Publication number
ATE209036T1
ATE209036T1 AT96917855T AT96917855T ATE209036T1 AT E209036 T1 ATE209036 T1 AT E209036T1 AT 96917855 T AT96917855 T AT 96917855T AT 96917855 T AT96917855 T AT 96917855T AT E209036 T1 ATE209036 T1 AT E209036T1
Authority
AT
Austria
Prior art keywords
imidazo
quinolones
neuroprotective drugs
conditions
neuroprotective
Prior art date
Application number
AT96917855T
Other languages
English (en)
Inventor
Donald B Carter
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Application granted granted Critical
Publication of ATE209036T1 publication Critical patent/ATE209036T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT96917855T 1995-06-15 1996-06-03 Verwendung von imidazo(a,5-a)quinolonen als neuroprotektive arzneimittel ATE209036T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24695P 1995-06-15 1995-06-15
PCT/US1996/007952 WO1997000074A1 (en) 1995-06-15 1996-06-03 USE OF IMIDAZO[1,5-a]QUINOLONES AS NEUROPROTECTIVE AGENTS

Publications (1)

Publication Number Publication Date
ATE209036T1 true ATE209036T1 (de) 2001-12-15

Family

ID=21690598

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96917855T ATE209036T1 (de) 1995-06-15 1996-06-03 Verwendung von imidazo(a,5-a)quinolonen als neuroprotektive arzneimittel

Country Status (10)

Country Link
US (1) US5935970A (de)
EP (1) EP0833638B1 (de)
JP (1) JP2001518056A (de)
AT (1) ATE209036T1 (de)
AU (1) AU6025996A (de)
DE (1) DE69617237T2 (de)
DK (1) DK0833638T3 (de)
ES (1) ES2167569T3 (de)
PT (1) PT833638E (de)
WO (1) WO1997000074A1 (de)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3454579A (en) * 1967-08-17 1969-07-08 American Cyanamid Co Imidazo(1,5-a)quinolin-1-one and thione derivatives
US4350814A (en) * 1979-10-22 1982-09-21 Ici Americas Inc. Pyrrolo [3,4-c]quinoline compounds
FR2593179B1 (fr) * 1986-01-22 1988-04-01 Synthelabo Derives d'imidazo(1,2-a)quinoleines, leur preparation et leur application en therapeutique
US5190951A (en) * 1990-10-19 1993-03-02 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
USRE35840E (en) * 1993-11-19 1998-07-07 Pharmacia & Upjohn Company Imidazo 1,5-a!quinolines for treatment of anxiety and sleep disorders
US5580877A (en) * 1994-04-25 1996-12-03 Merck Sharp & Dohme Ltd. Pyrazolo-quinoline derivatives for treating cerebral ischemia

Also Published As

Publication number Publication date
EP0833638B1 (de) 2001-11-21
DE69617237D1 (de) 2002-01-03
WO1997000074A1 (en) 1997-01-03
EP0833638A1 (de) 1998-04-08
PT833638E (pt) 2002-05-31
US5935970A (en) 1999-08-10
ES2167569T3 (es) 2002-05-16
AU6025996A (en) 1997-01-15
DE69617237T2 (de) 2002-06-27
DK0833638T3 (da) 2002-05-21
JP2001518056A (ja) 2001-10-09

Similar Documents

Publication Publication Date Title
DK0877734T3 (da) Quinolin- og quinazolinforbindelser, der er egnede i terapi
TR199600265A1 (tr) Kinazolin türevleri.
DE69618959D1 (de) Pyrimidone und ihre verwendug als fungizide
AU9693998A (en) Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
ATE213245T1 (de) Triazolo(4,5-d)pyrimidinyl-derivate und ihre verwendung als medikamente
AU2383197A (en) Substituted pyridines/pyrimidines, process for their production and their use as pest control agents
FI901148A7 (fi) Tetrahydrokinoliinijohdannaisia, jotka ovat käyttökelpoisia hermojen rappeutumistilojen hoidossa
NO972391L (no) 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav
AU8330898A (en) Substituted heterocycles and their use in medicaments
DE69614149D1 (de) Chinolinderivate als antimalariamittel
AU6459596A (en) Methods of treatment of neurological diseases by interferon antagonists
ZA968990B (en) Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases.
AU3524995A (en) Method for treatment of cancers by regulating the activity of ras proteins
FI934862L (fi) Foerfarande foer kvantitativ rening av glykolipider
MY110149A (en) Compounds for the treatment of neurodegenerative disorders
DE69822297D1 (de) Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten
AU1860995A (en) Quinoline or quinazoline derivatives as anti-inflammatory agents, in particular for treating arthritis
NO892505L (no) Behandling av vandige dispersjoner.
AU668241B2 (en) Condensed heterocyclic compounds, their production and use
LV11940A (lv) Melatonina pielietojums personu arstesanai kuras cies no zalu atkaribas
NO981822L (no) Anvendelse av proteinet GAX for behandling av cancer
EE03437B1 (et) Benseenamiidid neurodegeneratiivsete haiguste ravimiseks
ZA966842B (en) Transdermal administration of vorozole.
DE69616598D1 (de) Verwendung von tricyclischen 1,4-dihydro-1,4-dioxo-1h-naphalen derivaten, neue verbindungen und ihre therapeutische verwendung
DE69611303D1 (de) Benzolsulfonamidderivate, ihre herstellung und ihre therapeutische verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee